Skip to search formSkip to main contentSkip to account menu

draflazine

Known as: 1-Piperazineacetamide, 2-(aminocarbonyl)-N-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-, 2-aminocarbonyl-N-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)-pentyl)-1-piperazineacetamide 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Background and methods The role of the endogenous purine nucleoside, adenosine, in nociception is well established. Inhibition of… 
2008
2008
Mammalian cells require specific transport mechanisms for the cellular uptake and release of endogenous nucleosides such as… 
2001
2001
We explored the effects of the nucleoside transport inhibitor draflazine on regional blood flow, O2 extraction capabilities, and… 
1999
1999
It was previously shown that systemic hyperinsulinemia induces vasodilation in human skeletal muscle. The mechanism mediating… 
1999
1999
BACKGROUND: Adenosine plays a major role in protecting ischaemic myocardium and may potentiate ischaemic preconditioning… 
1997
1997
BACKGROUND Adenosine has several potentially cardioprotective effects. We hypothesized that the effects of endogenous adenosine… 
1996
1996
Objectives In a randomised, double-blind, placebo controlled study, we evaluated the tolerability and safety of draflazine, a… 
1995
1995
In 6 healthy male volunteers a placebo‐controlled, double‐blind, randomized, crossover trial was done to assess the effect of 1… 
1993
1993
OBJECTIVE R 75,231, a potent and specific nucleoside transport inhibitor, largely prevents cardiac damage and death in…